粘细菌来源的抗HIV活性次级代谢产物研究进展  

Progresses in Myxobacterial Anti-HIV Secondary Metabolites Research

作　　者：付达华[1] 熊典虹[1] 李敏湘 FU Da-hua;XIONG Dian-hong;LI Min-xiang(Department of Pharmacy,Zhangzhou Health Vocational College,Zhangzhou 363000,China)

机构地区：[1]漳州卫生职业学院药学系

出　　处：《海峡药学》2020年第1期47-51,共5页Strait Pharmaceutical Journal

基　　金：漳州市科技计划项目(ZZ2013J14)

摘　　要：艾滋病对人类健康造成了巨大的威胁,对公众健康安全提出了巨大的挑战。很多时候,艾滋病患者因合并感染导致病情进一步恶化。当前使用的抗病毒药物因药效问题及易产生抗药性等问题,导致抗病毒效果有限。因此,急需开发具有广谱活性、药效不断提高、作用机制新颖的抗病毒药物。粘细菌能产生大量结构和功能独特的生物活性化合物,其生物活性包括抗肿瘤、抗病毒、抗真菌、抗细菌等。本文对粘细菌来源的抗HIV活性次级代谢产物进行回顾。AIDS poses a severe threat to human health and a great challenge to public health and safety.In many cases,illnesses are further aggravated due to co-infection.The antiviral drugs currently used are limited due to their efficacy and drug resistance.Therefore,it is urgent to develop antiviral drugs with broad spectrum activity,increasing efficacy and novel mechanism of action.Myxobacteria can produce a large number of bioactive compounds with unique structure and function,including anti-tumor,anti-virus,anti-fungal,anti-bacterial and so on.The present review looks at myxobacteria-derived anti-HIV secondary metabolites.

关 键 词：粘细菌 HIV 抗病毒 次级代谢产物 

分 类 号：R917[医药卫生—药物分析学]